STOCK TITAN
  1. Home
  2. Sec-filings
  3. VVX
  4. [8-K] V2X, Inc. Reports Material Event

V2X, Inc. (VVX) Chief Growth Officer exits role with $331,975 incentive payment

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

V2X, Inc. reported that Dr. L. Roger Mason, Jr. resigned, effective August 7, 2026, from his role as Senior Vice President and Chief Growth Officer and from all positions with the company’s direct and indirect subsidiaries to serve as Director of the National Reconnaissance Office of the U.S. Department of War. The company states that his resignation is not due to any disagreement regarding its operations, policies, or practices.

In connection with a separation agreement and general release dated August 6, 2026, the Compensation and Human Capital Committee approved an AIP Payment of $331,975, representing a prorated portion of his 2026 Annual Incentive Plan award at target for employment from January through July 2026. Chief Executive Officer Jeremy C. Wensinger will assume Dr. Mason’s responsibilities until a successor is appointed. The Release Agreement is filed as Exhibit 10.1.

Positive

  • None.

Negative

  • Chief Growth Officer resignation: Senior Vice President and Chief Growth Officer Dr. L. Roger Mason, Jr. resigned effective August 7, 2026, creating a leadership transition while the company searches for a successor.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
AIP Payment $331,975 Prorated portion of Dr. Mason’s 2026 Annual Incentive Plan award at target for January–July 2026
Resignation effective date August 7, 2026 Effective date of Dr. Mason’s resignation from V2X and its subsidiaries
Release Agreement date August 6, 2026 Date of Release Agreement between V2X and Dr. Mason
Annual Incentive Plan financial
"The AIP Payment amount was equal to a prorated portion of his 2026 Annual Incentive Plan award"
Release Agreement regulatory
"entering into a separation agreement and general release (the "Release Agreement"), dated August 6, 2026"
general release regulatory
"whereby Dr. Mason agreed to release all claims in favor of the Company, among other things"
Compensation and Human Capital Committee financial
"the Compensation and Human Capital Committee of the Board of Directors of the Company approved a payment"
A compensation and human capital committee is a board-level group that sets and oversees executive pay, employee incentive plans, hiring and retention strategies, succession planning, and workplace policies. Think of it as the company’s talent and pay steering team — it shapes who gets hired or promoted, how employees are rewarded, and how workforce risks are managed. Investors care because those choices drive labor costs, company performance, leadership stability and reputation, all of which affect long-term value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

Why did V2X, Inc. (VVX) announce the resignation of Dr. L. Roger Mason, Jr.?
V2X, Inc. disclosed that Dr. L. Roger Mason, Jr. resigned as Senior Vice President and Chief Growth Officer effective August 7, 2026, to serve as Director of the National Reconnaissance Office of the U.S. Department of War, and also left all subsidiary positions.

Did Dr. Mason’s resignation from V2X, Inc. (VVX) involve any disagreement with the company?
The company states that Dr. Mason’s resignation is not the result of any disagreement with V2X on matters relating to its operations, policies, or practices, indicating an orderly leadership transition rather than a dispute-driven departure.

What separation payment did V2X, Inc. (VVX) approve for Dr. Mason?
V2X’s Compensation and Human Capital Committee approved an AIP Payment of $331,975 for Dr. Mason, representing a prorated portion of his 2026 Annual Incentive Plan award at target based on employment from January through July 2026.

Who will assume the Chief Growth Officer responsibilities at V2X, Inc. (VVX)?
Chief Executive Officer Jeremy C. Wensinger will temporarily assume Dr. Mason’s role and responsibilities until the company appoints a successor, providing interim coverage of growth-related leadership functions.

What is the Release Agreement mentioned by V2X, Inc. (VVX) in connection with Dr. Mason’s resignation?
Dr. Mason and V2X entered into a Release Agreement dated August 6, 2026, under which he agreed to release all claims in favor of the company, among other terms; the full agreement is filed as Exhibit 10.1.
false000160154800016015482026-08-062026-08-06


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): August 6, 2026
 
 
V2X, Inc.
(Exact Name of Registrant as Specified in Its Charter)
 
 
Indiana
(State or Other Jurisdiction of Incorporation)
 
001-3634138-3924636
(Commission(IRS Employer
File Number)Identification No.)
 
2100 Reston Parkway, Suite 300
Reston, VA 20191
(Address of Principal Executive Offices) (Zip Code)
 
(571) 481-2000
(Registrant's Telephone Number, Including Area Code)
 
Securities Registered Under Section 12(b) of the Act:
 
Title of each class
Trading
symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.01 Per ShareVVXNew York Stock Exchange
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ¨
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 



Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of L. Roger Mason, Jr. as Chief Growth Officer

On August 7, 2026, Dr. L. Roger Mason, Jr. resigned from his position as: (i) Senior Vice President and Chief Growth Officer of V2X, Inc. (the “Company”) and (ii) all positions held for each direct and indirect subsidiary of the Company, each effective immediately, to serve as the Director of the National Reconnaissance Office of the U.S. Department of War.

In anticipation of Dr. Mason’s resignation and in recognition for his contributions to the Company and for entering into a separation agreement and general release (the "Release Agreement"), dated August 6, 2026, with the Company, whereby Dr. Mason agreed to release all claims in favor of the Company, among other things, the Compensation and Human Capital Committee of the Board of Directors of the Company approved a payment to Dr. Mason in an amount of $331,975 (“AIP Payment”). The AIP Payment amount was equal to a prorated portion of his 2026 Annual Incentive Plan award at target based on the number of full months employed with the Company (from January 2026 through July 2026) prior to his confirmation as the Director of the National Reconnaissance Office of the U.S. Department of War.

Dr. Mason’s resignation from the Company is not a result of any disagreement with the Company on any matter relating to its operations, policies or practices. Mr. Jeremy C. Wensinger, the Company’s Chief Executive Officer, will assume Dr. Mason’s role and responsibilities until such time as Dr. Mason’s successor has been appointed.

The foregoing description of the Release Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Release Agreement, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

Item 9.01
Financial Statements and Exhibits.
(d) Exhibits

The exhibits listed in the following Exhibit Index are filed as part of this Current Report.
Exhibit No.Description
10.1
Release Agreement, dated August 6, 2026



SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated: August 10, 2026V2X, INC.
By:/s/ Sarita B. Malakar
Sarita B. Malakar
Corporate Secretary
 
 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

5 documents

Agreements & Contracts

Other Documents